Carbocaine with Neo-Cobefrin Shortage: What Providers and Prescribers Need to Know in 2026

Carbocaine 2% with Neo-Cobefrin (mepivacaine hydrochloride 2% with levonordefrin 1:20,000) has long been a reliable staple of dental anesthesia protocols. Its unique vasoconstrictor — levonordefrin, which produces less cardiovascular stimulation than epinephrine — has made it a preferred choice for medically complex patients. But its niche ingredient profile and limited manufacturing base have historically made it one of the more supply-vulnerable anesthetic products on the market.

This guide is designed for dentists, oral surgeons, periodontists, endodontists, and other dental prescribers managing Carbocaine with Neo-Cobefrin supply uncertainty in their practices.

Current Supply Status (2026)

Carbocaine 2% with Neo-Cobefrin (NDC 0362-0931-05) is not listed on the FDA's official drug shortage database as of 2026. The product is manufactured by Septodont, Inc. and distributed through major dental supply channels. However, providers should be aware that regional and distributor-level gaps in availability can occur without formal FDA shortage designation — particularly given the product's reliance on levonordefrin, a vasoconstrictor sourced from a limited number of API suppliers.

Clinical Context: Why Levonordefrin Matters

Levonordefrin (Neo-Cobefrin) is the only dental vasoconstrictor available in North American cartridges besides epinephrine. Its alpha-adrenergic activity provides adequate vasoconstriction to prolong anesthesia duration — up to 2.5 hours in the maxilla and 5.5 hours in the mandible — while producing less beta-adrenergic cardiovascular stimulation than epinephrine at equivalent vasoconstrictive concentrations.

This pharmacological profile makes it clinically valuable for patients with controlled hypertension, arteriosclerotic heart disease, or those for whom epinephrine-containing solutions require extra caution. The maximum recommended levonordefrin dose is 1 mg per appointment; the maximum mepivacaine dose is 6.6 mg/kg (3 mg/lb) up to a maximum of 400 mg.

High-Risk Drug Interactions to Flag Before Administering

Before using Carbocaine with Neo-Cobefrin (or any levonordefrin-containing product), review the patient's medication list for:

MAO inhibitors (MAOIs): Co-administration can cause severe, prolonged hypertension. Concurrent use should be avoided; delay elective procedures if possible.

Tricyclic antidepressants (TCAs): May potentiate the vasopressor effect of levonordefrin, producing severe hypertension. Exercise caution and consider a vasoconstrictor-free alternative.

Ergot-type oxytocic drugs: Risk of severe persistent hypertension or cerebrovascular accident.

Potent halogenated inhalation anesthetics: Risk of serious cardiac arrhythmias; use extreme caution if patient is under general anesthesia simultaneously.

Evidence-Based Alternatives During a Shortage

When Carbocaine with Neo-Cobefrin is unavailable, consider these evidence-based substitutes:

Mepivacaine 3% plain: Best option when any vasoconstrictor is contraindicated. Short procedure duration (20 min maxilla / 40 min mandible pulpal). Suitable for medically compromised patients.

Prilocaine 4% plain (nerve block only): Intermediate duration (40–60 min pulpal). Vasoconstrictor-free with good mandibular block performance. Avoid in patients with methemoglobinemia risk.

Lidocaine 2% with 1:200,000 epinephrine (via articaine or prilocaine): Lower epinephrine concentration reduces cardiovascular stimulation while still extending duration. Consult ASA classification and patient history.

Articaine 4% with 1:200,000 epinephrine: Good bone penetration, lower epinephrine dose. Appropriate for many ASA III patients with physician consultation.

Sourcing Strategies for Your Practice

Check multiple dental distributors simultaneously: Henry Schein, Patterson Dental, Darby Dental, Safco Dental Supply, Supply Clinic, and Sky Dental Supply may have stock when your primary distributor does not.

Contact Septodont directly: As the primary US manufacturer, Septodont can direct you to current authorized distributors with stock.

Check for generic equivalents: Mepivacaine 2%/levonordefrin 1:20,000 is available from other manufacturers under brand names like Polocaine Dental and Scandonest 2% L.

Consider a specialty dental pharmacy for compounded formulations if commercial supply is unavailable and the clinical need is urgent.

Communicating with Patients During a Shortage

When switching anesthetics due to supply constraints, transparency with patients is important. Key communication points:

Explain that you are using a clinically equivalent or appropriate alternative due to supply issues

Review the patient's allergy history and medical conditions before substituting any anesthetic

Document the switch in the patient record with clinical rationale

For medically complex patients requiring levonordefrin specifically, consider scheduling delay if supply is expected to normalize soon

Help Your Patients Find This Medication

If your practice is impacted by supply gaps, consider directing affected patients to medfinder for providers, which helps dental offices and patients locate nearby providers with specific medications in stock. Also see our guide on how to help your patients find Carbocaine with Neo-Cobefrin in stock.